Intranasal Delivery of Rotigotine to the Brain With Lactoferrin-Modified PEG-PLGA Nanoparticles for Parkinson’s Disease Treatment

International Journal of Nanomedicine - New Zealand
doi 10.2147/ijn.s120939
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Current Approaches to the Treatment of Parkinson’s Disease

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2008English

Deep Brain Stimulation for the Treatment of Parkinson’s Disease: Efficacy and Safety

Degenerative Neurological and Neuromuscular Disease
2012English

Liposome Delivery Systems for the Treatment of Alzheimer’s Disease

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2018English

The Role of Rasagiline in the Treatment of Parkinson’s Disease

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2010English

Depression in Parkinson’s Disease

Journal of Parkinsonism and Restless Legs Syndrome
2012English

Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy

Pharmaceutics
Pharmaceutical Science
2020English

Formulation of Functionalized PLGA–PEG Nanoparticles for in Vivo Targeted Drug Delivery

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2007English

Update on the Treatment of Parkinson’s Disease Psychosis: Role of Pimavanserin

Neuropsychiatric Disease and Treatment
2017English

Neuropsychiatric Symptoms in Untreated Parkinson’s Disease

Neuropsychiatric Disease and Treatment
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy